Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
PCV25 Optimal Usage of Sacubitril/Valsartan For...
Conference

PCV25 Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions

Authors

Haddad P; McKelvie R

Volume

20

Publisher

Elsevier

Publication Date

10 2017

DOI

10.1016/j.jval.2017.08.1170

Conference proceedings

Value in Health

Issue

9

ISSN

1098-3015